Failure of Hepatic Insulin Clearance via CEACAM1-Mediated Endocytosis: The Missing Physiological Link Between Proinsulin Misfolding, Hyperinsulinemia, and Metabolic Complications in Type 2 Diabetes, Obesity, and NAFLD

Type 2 diabetes mellitus (T2DM), projected to affect 700 million individuals by 2045, may be driven by a hypothesized physiological axis where impaired hepatic insulin clearance, mediated by CEACAM1 endocytosis, links proinsulin misfolding to chronic hyperinsulinemia, exacerbating T2DM, obesity, and non-alcoholic fatty liver disease (NAFLD). Approximately 50–80% of proinsulin, synthesized at ~6000 molecules per second, undergoes 5–10% misfolding due to disrupted disulfide bonds (B7-A7, B19-A20, A6-A11) under endoplasmic reticulum (ER) stress, compounded by glutathione (GSH) depletion, which primarily impairs protein disulfide isomerase (PDI) function critical for insulin synthesis. Hepatic clearance involves CEACAM1 binding, insulin receptor isoform B (IR-B) tyrosine 960 autophosphorylation, AP-2/clathrin/dynamin vesicle formation, Rab5-mediated acidification (pH 5.5), Rab7 trafficking, and lysosomal cathepsin B/D hydrolysis, supported by IR-B–IRS-1 tyrosine 608–PI3K–PDK1–Akt (Ser473)–GSK3β signaling. ER stress activates the unfolded protein response (UPR: IRE1α-XBP1, PERK-eIF2α, ATF6), increasing clearance demand.

When clearance fails, misfolded proinsulin accumulates, driving hyperinsulinemia, which promotes insulin resistance, activates mTORC1–SREBP-1c-mediated lipogenesis and VLDL export, and contributes to NAFLD and obesity, as observed in CEACAM1 knockout models. The Hepatic Insulin Clearance Index (HICI), derived from a 50-g glucose challenge yielding a C-peptide/insulin ratio<1, may diagnose impaired clearance with greater sensitivity than HOMA-IR. Emerging tools, such as cryo-EM and portal vein proteomics, could quantify misfolded aggregates and elucidate NAFLD connections. Potential therapeutic strategies, including CEACAM1 enhancers and IR-B agonists, may target this clearance axis. This hypothesis underscores hepatic insulin clearance as a potential mediator of insulin resistance and its role in diseases linked to chronic hyperinsulinemia.

1. Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020). The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). Journal of diabetes research, 2020, 3920196. doi: https://doi.org/10.1155/2020/3920196

2. Najjar, S. M., & Perdomo, G. (2019). Hepatic Insulin Clearance: Mechanism and Physiology. Physiology (Bethesda, Md.), 34(3), 198–215. doi: https://doi.org/10.1152/physiol.00048.2018

3. Sun, J., Cui, J., He, Q., Chen, Z., Arvan, P., & Liu, M. (2015). Proinsulin misfolding and endoplasmic reticulum stress during the development and progression of diabetes. Molecular aspects of medicine, 42, 105–118. doi: https://doi.org/10.1016/j.mam.2015.01.001

4. Arunagiri, A., Haataja, L., Cunningham, C. N., Shrestha, N., Tsai, B., Qi, L., Liu, M., & Arvan, P. (2018). Misfolded proinsulin in the endoplasmic reticulum during development of beta cell failure in diabetes. Annals of the New York Academy of Sciences, 1418(1), 5–19. doi: https://doi.org/10.1111/nyas.13531

5. Bertolotti, A., Zhang, Y., Hendershot, L. M., Harding, H. P., & Ron, D. (2000). Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nature cell biology, 2(6), 326–332. doi: https://doi.org/10.1038/35014014

6. Shen, J., Chen, X., Hendershot, L., & Prywes, R. (2002). ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. Developmental cell, 3(1), 99–111. doi: https://doi.org/10.1016/s1534-5807(02)00203-4

7. Horwitz, D. L., Starr, J. I., Mako, M. E., Blackard, W. G., & Rubenstein, A. H. (1975). Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. The Journal of clinical investigation, 55(6), 1278–1283. doi: https://doi.org/10.1172/JCI108047

8. Poy, M. N., Yang, Y., Rezaei, K., Fernström, M. A., Lee, A. D., Kido, Y., Erickson, S. K., & Najjar, S. M. (2002). CEACAM1 regulates insulin clearance in liver. Nature genetics, 30(3), 270–276. doi: https://doi.org/10.1038/ng840

9. Huang, F., Jiang, X., & Sorkin, A. (2003). Tyrosine phosphorylation of the beta2 subunit of clathrin adaptor complex AP-2 reveals the role of a di-leucine motif in the epidermal growth factor receptor trafficking. The Journal of biological chemistry, 278(44), 43411–43417. doi: https://doi.org/10.1074/jbc.M306072200

10. Mulligan, R. J., & Winckler, B. (2023). Regulation of Endosomal Trafficking by Rab7 and Its Effectors in Neurons: Clues from Charcot-Marie-Tooth 2B Disease. Biomolecules, 13(9), 1399. doi: https://doi.org/10.3390/biom13091399

11. Yadati, T., Houben, T., Bitorina, A., & Shiri-Sverdlov, R. (2020). The Ins and Outs of Cathepsins: Physiological Function and Role in Disease Management. Cells, 9(7), 1679. doi: https://doi.org/10.3390/cells9071679

12. Hulse, R. E., Ralat, L. A., & Wei-Jen, T. (2009). Structure, function, and regulation of insulin-degrading enzyme. Vitamins and hormones, 80, 635–648. doi: https://doi.org/10.1016/S0083-6729(08)00622-5

13. Eldar-Finkelman, H., & Krebs, E. G. (1997). Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proceedings of the National Academy of Sciences of the United States of America, 94(18), 9660–9664. doi: https://doi.org/10.1073/pnas.94.18.9660

14. Moslehi, A., & Hamidi-Zad, Z. (2018). Role of SREBPs in Liver Diseases: A Mini-review. Journal of clinical and translational hepatology, 6(3), 332–338. doi: https://doi.org/10.14218/JCTH.2017.00061

15. Zavarzadeh, P. G., Panchal, K., Bishop, D., Gilbert, E., Trivedi, M., Kee, T., Ranganathan, S., & Arunagiri, A. (2025). Exploring proinsulin proteostasis: insights into beta cell health and diabetes. Frontiers in molecular biosciences, 12, 1554717. doi: https://doi.org/10.3389/fmolb.2025.1554717

16. Arunagiri, A., Haataja, L., Cunningham, C. N., Shrestha, N., Tsai, B., Qi, L., Liu, M., & Arvan, P. (2018). Misfolded proinsulin in the endoplasmic reticulum during development of beta cell failure in diabetes. Annals of the New York Academy of Sciences, 1418(1), 5–19. doi: https://doi.org/10.1111/nyas.13531

17. Zuber, C., Fan, J. Y., Guhl, B., & Roth, J. (2004). Misfolded proinsulin accumulates in expanded pre-Golgi intermediates and endoplasmic reticulum subdomains in pancreatic beta cells of Akita mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 18(7), 917–919. doi: https://doi.org/10.1096/fj.03-1210fje

18. Thomas, J., Klebanov, A., John, S., Miller, L. S., Vegesna, A., Amdur, R. L., Bhowmick, K., & Mishra, L. (2023). CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens. Genes & cancer, 14, 12–29. doi: https://doi.org/10.18632/genesandcancer.230

19. Haucke, V., & De Camilli, P. (1999). AP-2 recruitment to synaptotagmin stimulated by tyrosine-based endocytic motifs. Science (New York, N.Y.), 285(5431), 1268–1271. doi: https://doi.org/10.1126/science.285.5431.1268

20. Damke, H., Binns, D. D., Ueda, H., Schmid, S. L., & Baba, T. (2001). Dynamin GTPase domain mutants block endocytic vesicle formation at morphologically distinct stages. Molecular biology of the cell, 12(9), 2578–2589. doi: https://doi.org/10.1091/mbc.12.9.2578

21. Barbieri, M. A., Li, G., Colombo, M. I., & Stahl, P. D. (1994). Rab5, an early acting endosomal GTPase, supports in vitro endosome fusion without GTP hydrolysis. The Journal of biological chemistry, 269(29), 18720–18722.

22. Koike, S., & Jahn, R. (2024). Rab GTPases and phosphoinositides fine-tune SNAREs dependent targeting specificity of intracellular vesicle traffic. Nature communications, 15(1), 2508. doi: https://doi.org/10.1038/s41467-024-46678-x

23. Yoon, M. C., Hook, V., & O’Donoghue, A. J. (2022). Cathepsin B Dipeptidyl Carboxypeptidase and Endopeptidase Activities Demonstrated across a Broad pH Range. Biochemistry, 61(17), 1904–1914. doi: https://doi.org/10.1021/acs.biochem.2c00358

24. Tundo, G. R., Grasso, G., Persico, M., Tkachuk, O., Bellia, F., Bocedi, A., Marini, S., Parravano, M., Graziani, G., Fattorusso, C., & Sbardella, D. (2023). The Insulin-Degrading Enzyme from Structure to Allosteric Modulation: New Perspectives for Drug Design. Biomolecules, 13(10), 1492. doi: https://doi.org/10.3390/biom13101492

25. Solow, B. T., Harada, S., Goldstein, B. J., Smith, J. A., White, M. F., & Jarett, L. (1999). Differential modulation of the tyrosine phosphorylation state of the insulin receptor by IRS (insulin receptor subunit) proteins. Molecular endocrinology (Baltimore, Md.), 13(10), 1784–1798. doi: https://doi.org/10.1210/mend.13.10.0361

26. Thapa, N., Chen, M., Cryns, V. L., & Anderson, R. (2024). A p85 isoform switch enhances PI3K activation on endosomes by a MAP4- and PI3P-dependent mechanism. Cell reports, 43(5), 114119. doi: https://doi.org/10.1016/j.celrep.2024.114119

27. Dangelmaier, C., Manne, B. K., Liverani, E., Jin, J., Bray, P., & Kunapuli, S. P. (2014). PDK1 selectively phosphorylates Thr(308) on Akt and contributes to human platelet functional responses. Thrombosis and haemostasis, 111(3), 508–517. doi: https://doi.org/10.1160/TH13-06-0484

28. Aldroubi, B. G., Najjar, J. A., Youssef, T. S., Rizk, C. E., Abuamreh, B. A. M., Aramouni, K., Ghadieh, H. E., & Najjar, S. M. (2024). Cell-specific regulation of insulin action and hepatic fibrosis by CEACAM1. Metabolism and target organ damage, 4(4), 34. doi: https://doi.org/10.20517/mtod.2024.48

29. Lee, J.-H., & Lee, J. (2022). Endoplasmic Reticulum (ER) Stress and Its Role in Pancreatic β-Cell Dysfunction and Senescence in Type 2 Diabetes. International Journal of Molecular Sciences, 23(9), 4843. doi: https://doi.org/10.3390/ijms23094843

30. Zhang, Y., Lin, S., Yao, J., Cai, W., Chen, H., Aierken, A., Wang, Z., & Song, W. (2023). XBP1 splicing contributes to endoplasmic reticulum stress-induced human islet amyloid polypeptide up-regulation. Genes & diseases, 11(5), 101148. doi: https://doi.org/10.1016/j.gendis.2023.101148

31. Chakravarthi, S., Jessop, C. E., & Bulleid, N. J. (2006). The role of glutathione in disulphide bond formation and endoplasmicreticulum-generated oxidative stress. EMBO reports, 7(3), 271–275. doi: https://doi.org/10.1038/sj.embor.7400645

32. Zhu, Y. Y., Zhang, Q., Jia, Y. C., Hou, M. J., & Zhu, B. T. (2024). Protein disulfide isomerase plays a crucial role in mediating chemicallyinduced, glutathione depletion-associated hepatocyte injury in vitro and in vivo. Cell communication and signaling : CCS, 22(1), 431. doi: https://doi.org/10.1186/s12964-024-01798-1

33. Najjar S. M. (2002). Regulation of insulin action by CEACAM1. Trends in endocrinology and metabolism: TEM, 13(6), 240–245. doi: https://doi.org/10.1016/s1043-2760(02)00608-2

34. Hill, E., van Der Kaay, J., Downes, C. P., & Smythe, E. (2001). The role of dynamin and its binding partners in coated pit invagination and scission. The Journal of cell biology, 152(2), 309–323. doi: https://doi.org/10.1083/jcb.152.2.309

35. Authier, F., Metioui, M., Fabrega, S., Kouach, M., & Briand, G. (2002). Endosomal proteolysis of internalized insulin at the C-terminal region of the B chain by cathepsin D. The Journal of biological chemistry, 277(11), 9437–9446. doi: https://doi.org/10.1074/jbc.M110188200

36. Ponce-Lopez T. (2025). Peripheral Inflammation and Insulin Resistance: Their Impact on Blood-Brain Barrier Integrity and Glia Activation in Alzheimer’s Disease. International journal of molecular sciences, 26(9), 4209. doi: https://doi.org/10.3390/ijms26094209

37. Dangelmaier, C., Manne, B. K., Liverani, E., Jin, J., Bray, P., & Kunapuli, S. P. (2014). PDK1 selectively phosphorylates Thr(308) on Akt and contributes to human platelet functional responses. Thrombosis and haemostasis, 111(3), 508–517. doi: https://doi.org/10.1160/TH13-06-0484

38. Onyango A. N. (2022). Excessive gluconeogenesis causes the hepatic insulin resistance paradox and its sequelae. Heliyon, 8(12), e12294. doi: https://doi.org/10.1016/j.heliyon.2022.e12294

39. Ghadieh, H., Russo, L., Muturi, H., Ghanem, S., Manaserh, I., Noh, H. L., Suk, S., Kim, J., Gatto-Weis, C., Hill, J., & Najjar, S. (2019). SAT-151 Hyperinsulinemia-Driven Progressive Metabolic Dysfunction in Male Mice with Liver-Specific CEACAM1 Deletion. Journal of the Endocrine Society, 3(Suppl 1), SAT-151. doi: https://doi.org/10.1210/js.2019-SAT-151

40. Lee, W. The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes. Diagn Pathol 6, 40 (2011). doi: https://doi.org/10.1186/1746-1596-6-40

41. Yecies, J. L., Zhang, H. H., Menon, S., Liu, S., Yecies, D., Lipovsky, A. I., Gorgun, C., Kwiatkowski, D. J., Hotamisligil, G. S., Lee, C. H., & Manning, B. D. (2011). Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell metabolism, 14(1), 21–32. doi: https://doi.org/10.1016/j.cmet.2011.06.002

42. Liu, Y., Yang, X., Zhou, J. et al. OSGEP regulates islet β-cell function by modulating proinsulin translation and maintaining ER stress homeostasis in mice. Nat Commun, 15, 10479 (2024). doi: https://doi.org/10.1038/s41467-024-54905-8

43. Lappi, A. K., & Ruddock, L. W. (2011). Reexamination of the role of interplay between glutathione and protein disulfide isomerase. Journal of molecular biology, 409(2), 238–249. doi: https://doi.org/10.1016/j.jmb.2011.03.024

44. Ghilarducci, K., Cabana, V. C., Harake, A., Cappadocia, L., & Lussier, M. P. (2022). Membrane Targeting and GTPase Activity of Rab7 Are Required for Its Ubiquitination by RNF167. International Journal of Molecular Sciences, 23(14), 7847. doi: https://doi.org/10.3390/ijms23147847

45. Wang, T., Sun, L., Chen, C., Zhang, Y., He, B., Zhang, Y., Wang, Z., Xue, H., & Hao, Y. (2023). Phosphorylation at tyrosine 317 and 508 are crucial for PIK3CA/p110α to promote CRC tumorigenesis. Cell & bioscience, 13(1), 164. doi: https://doi.org/10.1186/s13578-023-01102-7

46. Wang, L., Li, J., Tang, P., Zhu, D., Tai, L., Wang, Y., Miyata, T., Woodgett, J. R., & Di, L. J. (2025). GSK3β Deficiency Expands Obese Adipose Vasculature to Mitigate Metabolic Disorders. Circulation research, 136(1), 91–111. doi: https://doi.org/10.1161/CIRCRESAHA.124.325187

47. Chen, X., Shi, C., He, M. et al. Endoplasmic reticulum stress: molecular mechanism and therapeutic targets. Sig Transduct Target Ther, 8, 352 (2023). doi: https://doi.org/10.1038/s41392-023-01570-w

48. Kim, W. M., Huang, Y. H., Gandhi, A., & Blumberg, R. S. (2019). CEACAM1 structure and function in immunity and its therapeutic implications. Seminars in immunology, 42, 101296. doi: https://doi.org/10.1016/j.smim.2019.101296

49. Humphries, W. H., 4th, Szymanski, C. J., & Payne, C. K. (2011). Endo-lysosomal vesicles positive for Rab7 and LAMP1 are terminal vesicles for the transport of dextran. PloS one, 6(10), e26626. doi: https://doi.org/10.1371/journal.pone.0026626

50. Talbot, K., Wang, H. Y., Kazi, H., Han, L. Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., Arvanitakis, Z., Schneider, J. A., Wolf, B. A., Bennett, D. A., Trojanowski, J. Q., & Arnold, S. E. (2012). Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. The Journal of clinical investigation, 122(4), 1316–1338. doi: https://doi.org/10.1172/JCI59903

51. Liu, L., Qi, X., Chen, Z., Shaw, L., Cai, J., Smith, L. H., Grant, M. B., & Boulton, M. E. (2013). Targeting the IRE1α/XBP1 and ATF6 arms of the unfolded protein response enhances VEGF blockade to prevent retinal and choroidal neovascularization. The American journal of pathology, 182(4), 1412–1424. doi: https://doi.org/10.1016/j.ajpath.2012.12.020

52. Sims, E. K., Geyer, S. M., Long, S. A., & Herold, K. C. (2023). High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment. Diabetologia, 66(12), 2283–2291. doi: https://doi.org/10.1007/s00125-023-06003-5

53. Patarrão, R. S., Meneses, M. J., Ghadieh, H. E., Herrera, L., Duarte, S., Ribeiro, R. T., Raposo, J. F., Schmitt, V., Singer, B. B., Gastaldelli, A., Penha-Gonçalves, C., Najjar, S. M., & Macedo, M. P. (2024). Insights into circulating CEACAM1 in insulin clearance and disease progression: Evidence from the Portuguese PREVADIAB2 study. European journal of clinical investigation, 54 Suppl 2(Suppl 2), e14344. doi: https://doi.org/10.1111/eci.14344

54. Al-Share, Q. Y., DeAngelis, A. M., Lester, S. G., Bowman, T. A., Ramakrishnan, S. K., Abdallah, S. L., Russo, L., Patel, P. R., Kaw, M. K., Raphael, C. K., Kim, A. J., Heinrich, G., Lee, A. D., Kim, J. K., Kulkarni, R. N., Philbrick, W. M., & Najjar, S. M. (2015). Forced Hepatic Overexpression of CEACAM1 Curtails Diet-Induced Insulin Resistance. Diabetes, 64(8), 2780–2790. doi: https://doi.org/10.2337/db14-1772

55. Russo, L., Muturi, H. T., Ghadieh, H. E., Ghanem, S. S., Bowman, T. A., Noh, H. L., Dagdeviren, S., Dogbey, G. Y., Kim, J. K., Heinrich, G., & Najjar, S. M. (2017). Liver-specific reconstitution of CEACAM1 reverses the metabolic abnormalities caused by its global deletion in male mice. Diabetologia, 60(12), 2463–2474. doi: https://doi.org/10.1007/s00125-017-4432-y

56. Horst, A. K., Najjar, S. M., Wagener, C., & Tiegs, G. (2018). CEACAM1 in Liver Injury, Metabolic and Immune Regulation. International journal of molecular sciences, 19(10), 3110. doi: https://doi.org/10.3390/ijms19103110

57. Ghadieh, H. E., Russo, L., Muturi, H. T., Ghanem, S. S., Manaserh, I. H., Noh, H. L., Suk, S., Kim, J. K., Hill, J. W., & Najjar, S. M. (2019). Hyperinsulinemia drives hepatic insulin resistance in male mice with liver-specific Ceacam1 deletion independently of lipolysis. Metabolism: clinical and experimental, 93, 33–43. doi: https://doi.org/10.1016/j.metabol.2019.01.008

58. Najjar, S. M., & Russo, L. (2014). CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH). Seminars in immunopathology, 36(1), 55–71. doi: https://doi.org/10.1007/s00281-013-0407-3

59. Zaidi, S., Asalla, S., Muturi, H. T., Russo, L., Abdolahipour, R., Belew, G. D., Iglesias, M. B., Feraudo, M., Leon, L., Kuo, E., Liu, X., Kumarasamy, S., Ghadieh, H. E., Gatto-Weis, C., Zarrinpar, A., Duarte, S., & Najjar, S. M. (2024). Loss of CEACAM1 in hepatocytes causes hepatic fibrosis. European journal of clinical investigation, 54(7), e14177. doi: https://doi.org/10.1111/eci.14177

60. Zaidi S, Asalla S, Muturi HT, et al. Loss of CEACAM1 in hepatocytes causes hepatic fibrosis. Eur J Clin Invest. 2024; 54:e14177. doi: https://doi.org/10.1111/eci.14177

61. Pivovarova, O., Bernigau, W., Bobbert, T., Isken, F., Möhlig, M., Spranger, J., Weickert, M. O., Osterhoff, M., Pfeiffer, A. F., & Rudovich, N. (2013). Hepatic insulin clearance is closely related to metabolic syndrome components. Diabetes care, 36(11), 3779–3785. doi: https://doi.org/10.2337/dc12-1203

62. Heinrich, G., Ghadieh, H. E., Ghanem, S. S., Muturi, H. T., Rezaei, K., Al-Share, Q. Y., Bowman, T. A., Zhang, D., Garofalo, R. S., Yin, L., & Najjar, S. M. (2017). Loss of Hepatic CEACAM1: A Unifying Mechanism Linking Insulin Resistance to Obesity and Non-Alcoholic Fatty Liver Disease. Frontiers in endocrinology, 8, 8. doi: https://doi.org/10.3389/fendo.2017.00008

63. Horst, A. K., Najjar, S. M., Wagener, C., & Tiegs, G. (2018). CEACAM1 in Liver Injury, Metabolic and Immune Regulation. International Journal of Molecular Sciences, 19(10), 3110. doi: https://doi.org/10.3390/ijms19103110

64. Raiborg, C., Bache, K. G., Mehlum, A., Stang, E., & Stenmark, H. (2001). Hrs recruits clathrin to early endosomes. The EMBO journal, 20(17), 5008–5021. doi: https://doi.org/10.1093/emboj/20.17.5008

65. Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018). Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cellular and molecular life sciences : CMLS, 75(18), 3313–3327. doi: https://doi.org/10.1007/s00018-018-2860-6

66. Heeren, J., & Scheja, L. (2021). Metabolic-associated fatty liver disease and lipoprotein metabolism. Molecular metabolism, 50, 101238. doi: https://doi.org/10.1016/j.molmet.2021.101238

67. Liu, M., Weiss, M. A., Arunagiri, A., Yong, J., Rege, N., Sun, J., Haataja, L., Kaufman, R. J., & Arvan, P. (2018). Biosynthesis, structure, and folding of the insulin precursor protein. Diabetes, obesity & metabolism, 20 Suppl 2(Suppl 2), 28–50. doi: https://doi.org/10.1111/dom.13378

68. Asare-Bediako, I., Paszkiewicz, R. L., Kim, S. P., Woolcott, O. O., Kolka, C. M., Burch, M. A., Kabir, M., & Bergman, R. N. (2018). Variability of Directly Measured First-Pass Hepatic Insulin Extraction and Its Association With Insulin Sensitivity and Plasma Insulin. Diabetes, 67(8), 1495–1503. doi: https://doi.org/10.2337/db17-1520

69. Nittka, S., Böhm, C., Zentgraf, H., & Neumaier, M. (2008). The CEACAM1-mediated apoptosis pathway is activated by CEA and triggers dual cleavage of CEACAM1. Oncogene, 27(26), 3721–3728. doi: https://doi.org/10.1038/sj.onc.1211033

70. Riahi, Y., Israeli, T., Cerasi, E., & Leibowitz, G. (2018). Effects of proinsulin misfolding on β-cell dynamics, differentiation and function in diabetes. Diabetes, obesity & metabolism, 20 Suppl 2, 95–103. doi: https://doi.org/10.1111/dom.13379

71. Rajpal, G., Schuiki, I., Liu, M., Volchuk, A., & Arvan, P. (2012). Action of protein disulfide isomerase on proinsulin exit from endoplasmic reticulum of pancreatic β-cells. The Journal of biological chemistry, 287(1), 43–47. doi: https://doi.org/10.1074/jbc.C111.279927

72. Fu, J., Gao, J., Liang, Z., & Yang, D. (2020). PDI-Regulated Disulfide Bond Formation in Protein Folding and Biomolecular Assembly. Molecules (Basel, Switzerland), 26(1), 171. doi: https://doi.org/10.3390/molecules26010171

73. Akl MM, Ahmed A. Sulfur-Dependent Disulfide Bond Disruption in Insulin Resistance: A Hypothesis. Advanced Pharmaceutical Bulletin, doi: https://doi.org/10.34172/apb.025.46067.

74. Ong, G., Ragetli, R., Mnich, K. et al. IRE1 signaling increases PERK expression during chronic ER stress. Cell Death Dis 15, 276 (2024). doi: https://doi.org/10.1038/s41419-024-06663-0

75. Cramer, C. N., Hubálek, F., Brand, C. L., Helleberg, H., Kurtzhals, P., & Sturis, J. (2024). Chain splitting of insulin: an underlying mechanism of insulin resistance?. npj metabolic health and disease, 2(1), 38. doi: https://doi.org/10.1038/s44324-024-00042-1

76. Ballatori, N., Krance, S. M., Notenboom, S., Shi, S., Tieu, K., & Hammond, C. L. (2009). Glutathione dysregulation and the etiology and progression of human diseases. Biological chemistry, 390(3), 191–214. doi: https://doi.org/10.1515/BC.2009.033

77. Pina, A. F., Borges, D. O., Meneses, M. J., Branco, P., Birne, R., Vilasi, A., & Macedo, M. P. (2020). Insulin: Trigger and Target of Renal Functions. Frontiers in cell and developmental biology, 8, 519. doi: https://doi.org/10.3389/fcell.2020.00519

78. Uehara, K., Sostre-Colón, J., Gavin, M., Santoleri, D., Leonard, K. A., Jacobs, R. L., & Titchenell, P. M. (2022). Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis. Cellular and molecular gastroenterology and hepatology, 13(6), 1625–1647. doi: https://doi.org/10.1016/j.jcmgh.2022.02.015

79. Choi, S. H., & Ginsberg, H. N. (2011). Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends in endocrinology and metabolism: TEM, 22(9), 353–363. doi: https://doi.org/10.1016/j.tem.2011.04.007

80. Vetrano, E., Rinaldi, L., Mormone, A., Giorgione, C., Galiero, R., Caturano, A., Nevola, R., Marfella, R., & Sasso, F. C. (2023). Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies. Biomedicines, 11(2), 468. doi: https://doi.org/10.3390/biomedicines11020468